[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
14-Feb-2011

[ | E-mail ] Share Share

Contact: Ushma Neill
press_releases@the-jci.org
734-546-5241
Journal of Clinical Investigation
@jclinicalinvest

New combination therapy for solid tumors?

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound (ABT-737) that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis. In addition, cells in hypoxic regions of human tumors xenografted in mice were susceptible to ABT-737-induced apoptotic cell death. As ABT-737 synergized with conventional chemotherapeutic agents in tumor-bearing mice, the authors suggest that such a combination of drugs could improve treatment of solid tumors.

###

TITLE: Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1

AUTHOR CONTACT:
Caroline Dive
Paterson Institute for Cancer Research, Manchester, United Kingdom.
Phone: 00.44.161.446.3036; Fax: 00.44.161.446.3109; E-mail: cdive@picr.man.ac.uk.

View this article at: http://www.jci.org/articles/view/43505?key=b39a1fa8ed3af3fab6a0



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.